Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Antineoplastic and immunomodulating drugs
Valemetostat
Другие языки:

    Valemetostat

    Подписчиков: 0, рейтинг: 0
    Valemetostat
    Valemetostat.svg
    Clinical data
    Trade names Ezharmia
    Other names Valemetostat tosilate (JAN); DS-3201; DS-3201b
    Identifiers
    • (2R)-7-Chloro-2-[4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide
    CAS Number
    PubChem CID
    UNII
    KEGG
    Chemical and physical data
    Formula C26H34ClN3O4
    Molar mass 488.03 g·mol−1

    Valemetostat (trade name Ezharmia) is a drug used for the treatment of adult T-cell leukemia/lymphoma (ATL).

    Valemetostat is an inhibitor of the enzymes enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2), which are implicated in the etiology of some forms of cancer including non-Hodgkin lymphomas.

    In Japan, valemetostat was approved in September 2022 for patients with relapsed or refractory adult T-cell leukemia/lymphoma.


    Новое сообщение